Filing summary
Company identification: The filing is for Diffusion Pharmaceuticals Inc. (formerly RestorGenex Corporation), not Cervomed Inc. It is an unaudited Form 10-Q for the quarter and six months ended June 30, 2016, filed August 15, 2016.
Business context and reporting period
Diffusion is a clinical-stage biotechnology company developing trans sodium crocetinate (TSC), intended to improve the effectiveness of radiation and chemotherapy by re-oxygenating tumors. Its lead programs target glioblastoma (GBM), pancreatic cancer and brain metastases. The company completed its merger with Diffusion Pharmaceuticals LLC on January 8, 2016. The merger is accounted for as a reverse acquisition, with Diffusion LLC treated as the accounting acquirer; prior-period comparisons therefore reflect Diffusion LLC on a standalone basis.
Key financial metrics
| Metric | Three months ended June 30, 2016 | Six months ended June 30, 2016 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $1.44 million | $3.80 million |
| General and administrative expense | $2.35 million | $6.21 million |
| Net loss | $3.81 million | $10.03 million |
| Basic and diluted loss per share | $0.04 | $0.10 |
At June 30, 2016, cash and cash equivalents were $3.01 million, working capital was $1.49 million, total assets were $19.92 million and total liabilities were $5.89 million. Convertible debt was $550,000 net on the balance sheet; its disclosed fair value was approximately $1.7 million. Six-month operating cash use was $7.49 million. Investing cash flow provided $8.50 million, principally from cash received in the merger, resulting in a $1.01 million net increase in cash. The filing reports no product gross margin; with no product sales, margin is not meaningful.
Changes versus prior comparable periods
- Second-quarter net loss increased from $1.33 million in 2015 to $3.81 million in 2016; six-month net loss increased from $2.57 million to $10.03 million.
- R&D expense rose to $1.44 million for the quarter and $3.80 million for six months, primarily due to TSC pancreatic-cancer development and higher GBM drug-manufacturing costs.
- G&A expense increased substantially, primarily reflecting merger-related costs, public-company and professional fees, investment-advisory services, and stock-based compensation. For the first six months, the company cited $2.0 million in acquisition costs and $3.1 million in public-company preparation and advisory fees.
- Cash rose from $2.00 million at December 31, 2015 to $3.01 million at June 30, 2016, largely reflecting the $8.5 million of cash received in the merger, partly offset by operating cash use.
Outlook, risks and unusual items
- Management said June 30 cash was expected to fund operations and research and development goals into the fourth quarter of 2016. Additional financing is required to continue planned development; no financing commitments were reported. Failure to raise funds could force the company to delay, reduce or discontinue programs, pursue collaborations or strategic alternatives, or cease operations.
- The company expected expenses and losses to increase as it advances TSC. It planned to pursue a 400-patient pivotal Phase III GBM study, subject to resources, and was discussing development in first-line pancreatic cancer with the FDA. The filing also describes possible Phase II pancreatic-cancer work within the next 12 months, conditional on funding.
- In August 2016, after quarter-end, the board decided to abandon RES-440 as outside the company’s core focus. The company expected a $932,000 noncash write-off in the third quarter and a related reduction in deferred tax liability.
- Two disclosed legal matters include an arbitration demand by former CEO Paul Feller, whose outcome and possible loss could not be estimated, and a former Diffusion LLC member’s lawsuit seeking specific performance involving 3,913,577 shares; trial was scheduled for March 2017. Management considered the claims without merit and intended to defend them.
- The merger’s purchase-price allocation was preliminary. Management reported disclosure controls effective at period-end and said integration of the pre-merger businesses’ processes and systems was ongoing.
Important facts for investors to verify
- Confirm the issuer is Diffusion Pharmaceuticals Inc.; the request metadata names a different company.
- Check available cash and subsequent financing, given management’s stated runway only into Q4 2016 and the absence of committed funding.
- Track regulatory and clinical progress, funding-dependent timing, and expected costs for the planned TSC studies.
- Review the third-quarter RES-440 impairment and its deferred-tax effect, as well as final merger purchase-price allocation.
- Monitor developments in the Feller arbitration and Schmidt litigation, including any resulting financial or dilution exposure.